MENU
PPH
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

PPH stock forecast, quote, news & analysis

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index... Show more

Category: #Health
A.I.Advisor
published price charts
A.I.Advisor
a Summary for PPH with price predictions
Nov 10, 2026

PPH in upward trend: price rose above 50-day moving average on October 14, 2026

PPH moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend. In 36 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on PPH as a result. In 72 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for PPH just turned positive on October 09, 2026. Looking at past instances where PPH's MACD turned positive, the stock continued to rise in 39 of 48 cases over the following month. The odds of a continued upward trend are 81%.

The 10-day moving average for PPH crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.

Following a +2.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where PPH advanced for three days, in 281 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

The Aroon Indicator entered an Uptrend today. In 253 of 297 cases where PPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for PPH moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 30 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

PPH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), McKesson Corp (NYSE:MCK), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN).

Industry description

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Market Cap

The average market capitalization across the VanEck Pharmaceutical ETF (PPH) ETF is 173.41B. The market cap for tickers in the group ranges from 2.2B to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is PRGO at 2.2B.

High and low price notable news

The average weekly price growth across all stocks in the VanEck Pharmaceutical ETF (PPH) ETF was 3%. For the same ETF, the average monthly price growth was 10%, and the average quarterly price growth was 21%. VTRS experienced the highest price growth at 10%, while CORT experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the VanEck Pharmaceutical ETF (PPH) ETF was -33%. For the same stocks of the ETF, the average monthly volume growth was -4% and the average quarterly volume growth was -1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 50
Price Growth Rating: 35
SMR Rating: 59
Profit Risk Rating: 51
Seasonality Score: 13 (-100 ... +100)